Dialyzed Leukocyte Extract (DLE) IMUNOR® As A Preventative Measure Against COVID-19

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F24%3AA2503AJB" target="_blank" >RIV/61988987:17110/24:A2503AJB - isvavai.cz</a>

Výsledek na webu

<a href="https://acquaintpublications.com/article/dialyzed_leukocyte_extract_dle_imunor_as_a_preventative_measure_against_covid_1996" target="_blank" >https://acquaintpublications.com/article/dialyzed_leukocyte_extract_dle_imunor_as_a_preventative_measure_against_covid_1996</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.38207/jcmphr/2024/mar05060346" target="_blank" >10.38207/jcmphr/2024/mar05060346</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dialyzed Leukocyte Extract (DLE) IMUNOR® As A Preventative Measure Against COVID-19

Popis výsledku v původním jazyce

Introduction: Original/review articles on the diagnosis, prevention and treatment of COVID-19 largely focus on the epidemiology,etiopathogenesis and management of severe cases resulting from SARS-CoV-2 infection. Less attention is paid to immunomodulatory drugsthat can favourably inform human innate immunity at the initial phases of infection. Therefore, a pilot monocentric study evaluating the efficacyof IMUNOR® in the prevention and mitigation of COVID-19 has been conducted.Material and methods: A monocentric pilot study (EudraCT 2020-005524-11) investigated 51 nurses at a university hospital during the thirdwave of the COVID-19 pandemic in the Czech Republic. The primary outcome measure was based on prevention success rates against SARSCoV-2 infection in outpatient and inpatient nurses during a 1-month and 2-month period in a high-risk professional setting, respectively, with a1-month follow-up. Secondary outcome measures focused on the severity of infection. The hospitalization rate in study participants andtolerability of IMUNOR® were also measured. A large-scale control group consisting of the remaining nurses in the same hospital was used.Results: During the study, only two nurses on the IMUNOR® preventative regimen suffered a mild COVID-19 infection. No hospitalizationwasrequired and a 2-week home-based symptomatic treatment wassufficient. A statistically highly significant preventative effect of IMUNOR®(p<0·00001) was documented for a total of 70 per cent of days. In the remaining days, statistical significance could not be established, therebeing one incapacitated subject only at a time.Discussion/conclusion: IMUNOR® appears to have a preventative potential against severe COVID-19 infection in high-risk professionalpopulations.

Název v anglickém jazyce

Dialyzed Leukocyte Extract (DLE) IMUNOR® As A Preventative Measure Against COVID-19

Popis výsledku anglicky

Introduction: Original/review articles on the diagnosis, prevention and treatment of COVID-19 largely focus on the epidemiology,etiopathogenesis and management of severe cases resulting from SARS-CoV-2 infection. Less attention is paid to immunomodulatory drugsthat can favourably inform human innate immunity at the initial phases of infection. Therefore, a pilot monocentric study evaluating the efficacyof IMUNOR® in the prevention and mitigation of COVID-19 has been conducted.Material and methods: A monocentric pilot study (EudraCT 2020-005524-11) investigated 51 nurses at a university hospital during the thirdwave of the COVID-19 pandemic in the Czech Republic. The primary outcome measure was based on prevention success rates against SARSCoV-2 infection in outpatient and inpatient nurses during a 1-month and 2-month period in a high-risk professional setting, respectively, with a1-month follow-up. Secondary outcome measures focused on the severity of infection. The hospitalization rate in study participants andtolerability of IMUNOR® were also measured. A large-scale control group consisting of the remaining nurses in the same hospital was used.Results: During the study, only two nurses on the IMUNOR® preventative regimen suffered a mild COVID-19 infection. No hospitalizationwasrequired and a 2-week home-based symptomatic treatment wassufficient. A statistically highly significant preventative effect of IMUNOR®(p<0·00001) was documented for a total of 70 per cent of days. In the remaining days, statistical significance could not be established, therebeing one incapacitated subject only at a time.Discussion/conclusion: IMUNOR® appears to have a preventative potential against severe COVID-19 infection in high-risk professionalpopulations.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Community Medicine and Public Health Reports

ISSN

2692-9899

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—